Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 1st Sakigake-Designated Product Earns Approval
December 18, 2017
- Ono Out-Licenses New I/O Candidate to Bristol-Myers
December 15, 2017
- New Pfizer Japan Chief Resolved to Grow Industry and Contribute to Society
December 15, 2017
- Chugai to Appoint COO Kosaka as CEO, with Nagayama Continuing to Serve as Chairman
December 15, 2017
- JCR’s BBB-Penetrating Hunter Syndrome Drug Delivers Positive PI/II Data; PII/III Study to Start Next Year
December 15, 2017
- Partnerships Hold Key to Success, Acquisition Not Our Goal: Takeda R&D Head
December 15, 2017
- Daiichi Sankyo to Shed Non-Cancer R&D Costs, Allocate More Resources to Oncology: CEO
December 14, 2017
- Daiichi Sankyo, Puma Tie Up on HER2-Targeting Combo Therapy
December 14, 2017
- Mitsubishi Tanabe Hooks Up with 2 Japanese Startups on ALS
December 14, 2017
- Ono Links Up with Canada’s Cyclenium on Macrocycles
December 13, 2017
- Kaketsuken Announces Biz Transfer to Meiji-Kumamoto JV
December 13, 2017
- Atezolizumab-Avastin Combo Delivers Positive Data in 1st Line RCC: Chugai
December 12, 2017
- Empliciti Shows Positive Response in Newly Diagnosed Japanese Myeloma Patients: BMS
December 12, 2017
- Japan Drug Makers Driven by Overseas Sales, See Tepid Revenue at Home: Jiho Tally
December 12, 2017
- Halaven/Keytruda Combo Delivers ORR of 26.4% in Triple-Negative Breast Cancer: Interim Data
December 11, 2017
- AbbVie Hopes Maviret Will Encourage Potential Hep C Patients to Get Treatment: Hepatitis Biz Head
December 11, 2017
- Daiichi Sankyo to Consider Further Development of DS-8201 for HER2 Low-Expressing Breast Cancer
December 11, 2017
- Sanofi, Asahi Kasei Pharma Tie Up for Anti RA Treatment Kevzara
December 11, 2017
- Janssen Files Guselkumab for Palmoplantar Pustulosis in Japan
December 11, 2017
- Emicizumab Every Four Weeks Delivers Positive Data, Chugai Plans New Dosage Filing Next Year
December 8, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…